NEW YORK – Thermo Fisher Scientific on Wednesday morning reported a 5 percent year-over-year increase in fourth quarter revenues.

纽约——Thermo Fisher Scientific周三上午报告称，第四季度收入同比增长5%。

For the three months ended Dec. 31, the company booked $11.40 billion in revenues, up from $10.89 billion in Q4 2023 and beating analysts' average estimate of $11.28 billion.

截至12月31日的三个月内，该公司实现收入114.0亿美元，高于2023年第四季度的108.9亿美元，超过了分析师的平均预期112.8亿美元。

'We finished 2024 with excellent financial performance, delivering strong growth on the top and bottom line in the fourth quarter,' Thermo Fisher Chairman, President, and CEO Marc Casper said in a statement. 'We are in a great position to deliver excellent performance in 2025 as we continue to create value for all of our stakeholders and build an even brighter future for our company.'.

赛默飞世尔董事长、总裁兼首席执行官马克·卡斯珀（MarcCasper）在一份声明中说，我们以优异的财务业绩完成了2024年，在第四季度实现了强劲的增长随着我们继续为所有利益相关者创造价值，为公司创造更加光明的未来，我们将在2025年取得优异的业绩。

By market segment, Thermo Fisher's life sciences solutions revenues grew 5 percent in Q4 to $2.60 billion from $2.47 billion a year ago. Analytical instruments revenues increased 7 percent to $2.19 billion from $2.04 billion. Specialty diagnostics revenues grew 5 percent to $1.16 billion from $1.11 billion.

按市场细分，赛默飞世尔生命科学解决方案的收入在第四季度增长了5%，从一年前的24.7亿美元增至26亿美元。分析仪器收入从20.4亿美元增至21.9亿美元，增长7%。专业诊断收入增长5%，从11.1亿美元增至11.6亿美元。

Laboratory products and biopharma services revenues were up 4 percent to $5.94 billion from $5.72 billion a year ago..

实验室产品和生物制药服务收入从一年前的57.2亿美元增长4%，达到59.4亿美元。。

Net income in Q4 totaled $1.83 billion, or $4.78 per share, compared to net income of $1.63 billion, or $4.20 per share, for the year-ago quarter. Adjusted EPS for the quarter was $6.10, beating analysts' consensus estimate of $5.94.

第四季度净收入总计18.3亿美元，即每股4.78美元，而去年同期净收入为16.3亿美元，即每股4.20美元。该季度调整后的每股收益为6.10美元，超出了分析师普遍预计的5.94美元。

The company's Q4 R&D costs grew 14 percent to $374.0 million from $327.0 million a year ago while its SG&A costs grew 10 percent to $1.85 billion from $1.67 billion.

该公司第四季度的研发成本从一年前的3.27亿美元增长了14%，达到3.74亿美元，而其销售和管理成本从16.7亿美元增长了10%，达到18.5亿美元。

For full-year 2023, Thermo Fisher reported $42.88 billion in revenues, essentially flat compared to $42.86 billion in 2023. Full-year revenues were in line with the company's guidance and in line with analysts' consensus estimate of $42.8 billion.

2023年全年，Thermo Fisher报告收入为428.8亿美元，与2023年的428.6亿美元基本持平。全年收入符合该公司的指导方针，也符合分析师普遍预计的428亿美元。

Full-year life sciences solutions revenues declined 4 percent year over year to $9.63 billion from $9.98 billion. Analytical instruments revenues rose 3 percent to $7.46 billion from $7.26 billion. Specialty diagnostics revenues increased 2 percent to $4.51 billion from $4.41 billion. Laboratory products and biopharma services revenues were flat at $23.2 billion compared to $23.0 billion in the prior year..

全年生命科学解决方案收入同比下降4%，从99.8亿美元降至96.3亿美元。分析仪器收入从72.6亿美元增至74.6亿美元，增长3%。专业诊断收入从44.1亿美元增至45.1亿美元，增长2%。实验室产品和生物制药服务收入持平，为232亿美元，而去年为230亿美元。。

Full-year R&D costs increased 4 percent year over year to $1.39 billion from $1.34 billion the year before while SG&A expenses were up 7 percent to $7.00 billion from $6.57 billion.

全年研发成本同比增长4%，从上年的13.4亿美元增至13.9亿美元，而销售和管理费用则从65.7亿美元增至70亿美元，增长7%。

Net income for 2024 grew to $6.34 billion, or $16.53 per share, from $6.00 billion, or $15.45 per share, in 2023. Adjusted EPS was $21.86, in line with the company's guidance and surpassing analysts' average estimate of $21.69.

2024年的净收入从2023年的60亿美元（每股15.45美元）增长到63.4亿美元（每股16.53美元）。调整后的每股收益为21.86美元，符合该公司的指导方针，超过了分析师平均估计的21.69美元。

Thermo Fisher finished 2024 with $4.01 billion in cash and cash equivalents and $1.56 billion in short-term investments.

Thermo Fisher在2024年完成了40.1亿美元的现金和现金等价物以及15.6亿美元的短期投资。

In morning trading on the New York Stock Exchange, Thermo Fisher’s shares were up more than 6 percent at $602.88.

在纽约证券交易所早盘交易中，赛默飞世尔的股价上涨超过6%，至602.88美元。